A look at Chronic Fatigue SyndromeKHAS-TVThey used a drug called Rituximab which is a beta lymphocyte depleting agent. It's a substance that blocks the antibody on the surface of the cells thus killing off the lymphoma cells. They treated the patie…
Ulcers and Stellate Scars on Bilateral Ankles—DiagnosisArchives of DermatologyIn addition, anticoagulation (heparin, low-molecular-weight heparin, warfarin, or aspirin), topical or systemic steroids, topical nitroglycerine paste, hyperbaric oxygen th…
Biogen Inks Deal With MAKScientificDaily Markets (blog)Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs (NYSE:ABT), and PEGylated interferon. Biogen has also been pretty active on …
Biogen Inks Deal with MAKScientific – Analyst BlogNASDAQBesides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. Biogen has also been pretty active on th…
Biogen Inks Deal with MAKScientificZacks.comBesides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs (ABT), and PEGylated interferon. Biogen has also been pretty active on the deal-making/…
Genmab Submits Protocol Amendment For Ofatumumab Phase 3 Head-to-head StudyNASDAQAccording to the amended protocol all patients recruited in the study which investigates ofatumumab plus chemotherapy versus rituximab plus chemotherapy in relapsed or ref…
Genmab Submits Protocol Amendment For Ofatumumab Phase 3 Head-to-head StudyRTT NewsAccording to the amended protocol all patients recruited in the study which investigates ofatumumab plus chemotherapy versus rituximab plus chemotherapy in relapsed or r…
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCLMarketWatch (press release)According to the amended protocol all patients recruited in the study which investigates ofatumumab plus chemotherapy versus rituximab plus chemotherap…
Roche's Avastin is top requested medicine in UK's cancer drugs fundPMLiVEOther drugs that received a high number of applications under the Cancer Drugs Fund included GSK's Tyverb (lapatinib), Roche's MabThera (rituximab) and Novartis…
Biogen Idec Takes Option to MAKScientific MS ProgramGenetic Engineering NewsBiogen Idec's MS pipeline comprises Peg IFN, BG-12, and daclizumab, all of which are in Phase III for relapsing forms. Anti-Lingo is being investigated in Phase I. The comp…